Federal contract award

75N91021F00002

PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA

Research the contractorView USAspending sourceSave to my pursuit research

Award details

Obligations, current value and potential value describe different measures; they are never added together.

FieldReported value
AgencyDepartment of Health and Human Services
OfficeNIH NCI
NAICS541714 — Research and Development in Biotechnology (except Nanobiotechnology)
PSCAN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
Parent award / vehicle75N91019D00020
Set-asideNot reported
Pricing typeFIRM FIXED PRICE
Obligations$1.0M
Current contract value$1.0M
Potential contract value / ceiling$1.0M
Start dateSep 15, 2021
Current end dateSep 14, 2026
Potential end dateSep 14, 2026
Latest award activityJun 17, 2026
Source loadedSep 26, 2026

Funding and modification history

Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.

DateModificationObligation changeDescription
Jun 17, 2026P00005$-9.2KPROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA
Aug 4, 2025P00004$0PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA
Jan 6, 2025P00003$0PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA
May 23, 2024P00002$184.2KPROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA
Feb 8, 2024P00001$0PROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA
Sep 13, 20210$845.8KPROJECT TITLE: FURTHER EVALUATION OF AMHR2-ED ANTIGENS FOR EPITHELIAL OVARIAN CARCINOMA

Research next steps

  1. Confirm the ordering vehicle and your eligibility or a qualified teaming route.
  2. Review the award scope and buyer evidence before making a bid/no-bid decision.